Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: A meta-analysis

Clinical Genetics

Volumn 85, Issue 1, 2014, Pages 43-48

  Tun, N M ^a   Villani, G ^b   Ong, K ^a   Yoe, L ^a   Bo, Z M ^c  

^a BROOKLYN HOSPITAL CENTER   (United States)

^b Ralph Lauren Center for Cancer Care and Prevention   (United States)

^c Springfield Regional Medical Center   (United States)

Author keywords

BRCA1; Breast cancer; Meta analysis; Triple negative

Indexed keywords

BRCA1 PROTEIN;

ARTICLE; ATTRIBUTABLE RISK; CANCER PATIENT; CANCER RISK; GENE MUTATION; GENETIC RISK; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; META ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

BRCA1; BREAST CANCER; META-ANALYSIS; TRIPLE-NEGATIVE;

FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; ODDS RATIO; PHENOTYPE; PUBLICATION BIAS; RISK; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84890247728     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12270     Document Type: Article

References (26)

1. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell 2007: 11: 103-105.
2. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history a combined analysis of 22 studies. Am J Hum Genet 2003: 72: 1117-1130.
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994: 343: 692-695.
4. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute, 2012.
5. Evans DG, Lalloo F, Cramer A et al. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009: 46: 811-817.
6. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013, from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed on May 10, 2013.
7. Higgins JPT, Green S, Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester, England; Hoboken, NJ: Wiley-Blackwell, 2008.
8. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002: 21: 1539-1558.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009: 151 (W264): 264-269.
10. Atchley DP, Albarracin CT, Lopez A et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008: 26: 4282-4288.
11. Bayraktar S, Gutierrez-Barrera AM, Lin H et al. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 2013: 30: 631-642.
12. Chen W, Pan K, Ouyang T et al. BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer. Breast Cancer Res Treat 2009: 117: 55-60.
13. Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat 2011: 129: 185-190.
14. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006: 24: 5652-5657.
15. Kwong A, Wong LP, Wong HN et al. Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hugo J 2009: 3: 63-76.
16. Li WF, Hu Z, Rao NY et al. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 2008: 110: 99-109.
17. Musolino A, Bella MA, Bortesi B et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer a population-based study. Breast 2007: 16: 280-292.
18. Ou J, Wu T, Sijmons R, Ni D, Xu W, Upur H. Prevalence of BRCA1 and BRCA2 germline mutations in breast cancer women of multiple ethnic region in Northwest China. J Breast Cancer 2013: 16: 50-54.
19. Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S. Clinical implications for BRCA gene mutation in breast cancer. Mol Biol Rep 2012: 39: 3097-3102.
20. Yip CH, Taib NA, Choo WY, Rampal S, Thong MK, Teo SH. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country. World J Surg 2009: 33: 2077-2081.
21. Zhang J, Pei R, Pang Z et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. Breast Cancer Res Treat 2012: 132: 421-428.
22. NCCN. Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian, Vol. 2013. National Comprehensive Cancer Network, 2013, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed on August 10, 2013.
23. Balmana J, Diez O, Rubio IT, Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011: 22 (Suppl. 6): vi31-vi34.
24. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Vol. 2013: National Institute for Health and Care Excellence (NICE), 2013, from http://www.nice.org.uk/nicemedia/live/14188/64202/64202.pdf. Accessed on July 31, 2013.
25. Walker E, Hernandez AV, Kattan MW. Meta-analysis: its strengths and limitations. Cleve Clin J Med 2008: 75: 431-439.
26. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000: 53: 1119-1129.